时间标签：数据日期 2026-11-05 · 生成时间 2026-11-05 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/11/02 – 2026/11/06 ｜ 情报发生日期 2026-11-05
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
摘要（PubMed 原文节选）
BACKGROUND: Physical frailty and sarcopenia are recognized as determinants of Alzheimer's disease (AD) progression, but their implications during anti-amyloid therapy remain unclear. We investigated their associations with longitudinal cognitive outcomes, treatment safety, tolerability, and plasma p-tau217 trajectories in patients with ea…
对本项目的价值
参考价值：属「脑老化与神经退行」方向；脑老化 / 神经退行 / 认知栏目可用作本项目文献库与综述素材。 ｜ 价值分 1.5/5（★★☆☆☆）
全文不可及原因
无 PMCID 且 Europe PMC / OpenAlex / Unpaywall 未提供可下载 OA 全文
原文题录
- 中文题名：基线躯体衰弱预测早期阿尔茨海默病 Lecanemab 治疗期间的临床结局：前瞻性真实世界队列研究
- 英文标题：Baseline Physical Frailty Predicts Clinical Outcomes During Lecanemab Therapy in Early Alzheimer's Disease: A Prospective Real-World Cohort Study.
- 期刊与标识：Aging and disease · PMID 42970319 · DOI 10.14336/AD.2026.0978